WO2018105805A1 - Method for isolating islet of newborn pig - Google Patents
Method for isolating islet of newborn pig Download PDFInfo
- Publication number
- WO2018105805A1 WO2018105805A1 PCT/KR2017/000273 KR2017000273W WO2018105805A1 WO 2018105805 A1 WO2018105805 A1 WO 2018105805A1 KR 2017000273 W KR2017000273 W KR 2017000273W WO 2018105805 A1 WO2018105805 A1 WO 2018105805A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- islets
- islet
- npccs
- newborn
- enzyme
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 28
- 210000000496 pancreas Anatomy 0.000 claims abstract description 23
- 102000004190 Enzymes Human genes 0.000 claims abstract description 19
- 108090000790 Enzymes Proteins 0.000 claims abstract description 19
- 230000004913 activation Effects 0.000 claims abstract description 8
- 230000001939 inductive effect Effects 0.000 claims abstract description 6
- 241000282887 Suidae Species 0.000 claims description 20
- 229940088598 enzyme Drugs 0.000 claims description 17
- 238000000926 separation method Methods 0.000 claims description 16
- 102000029816 Collagenase Human genes 0.000 claims description 10
- 108060005980 Collagenase Proteins 0.000 claims description 10
- 229960002424 collagenase Drugs 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000012981 Hank's balanced salt solution Substances 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- 239000001569 carbon dioxide Substances 0.000 claims description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 abstract description 10
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 7
- 238000002955 isolation Methods 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 2
- 238000002689 xenotransplantation Methods 0.000 abstract description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- 210000004153 islets of langerhan Anatomy 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000008103 glucose Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 239000008188 pellet Substances 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 7
- 229960005322 streptomycin Drugs 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 230000003914 insulin secretion Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 238000004020 luminiscence type Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229930182566 Gentamicin Natural products 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 229940064804 betadine Drugs 0.000 description 3
- YALMXYPQBUJUME-UHFFFAOYSA-L calcium chlorate Chemical compound [Ca+2].[O-]Cl(=O)=O.[O-]Cl(=O)=O YALMXYPQBUJUME-UHFFFAOYSA-L 0.000 description 3
- 229960003405 ciprofloxacin Drugs 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- -1 L-(+)-Glutamine 2-aminoglutamic acid Chemical compound 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- HDFXRQJQZBPDLF-UHFFFAOYSA-L disodium hydrogen carbonate Chemical compound [Na+].[Na+].OC([O-])=O.OC([O-])=O HDFXRQJQZBPDLF-UHFFFAOYSA-L 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- NAIXASFEPQPICN-UHFFFAOYSA-O p-nitrophenylphosphocholine Chemical compound C[N+](C)(C)CCOP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 NAIXASFEPQPICN-UHFFFAOYSA-O 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- ZUYKJZQOPXDNOK-UHFFFAOYSA-N 2-(ethylamino)-2-thiophen-2-ylcyclohexan-1-one;hydrochloride Chemical compound Cl.C=1C=CSC=1C1(NCC)CCCCC1=O ZUYKJZQOPXDNOK-UHFFFAOYSA-N 0.000 description 1
- NJERAXSSDSHLGE-UHFFFAOYSA-N 4-(2-fluorophenyl)-1,3,8-trimethyl-6h-pyrazolo[3,4-e][1,4]diazepin-7-one;hydrochloride Chemical compound Cl.N=1CC(=O)N(C)C(N(N=C2C)C)=C2C=1C1=CC=CC=C1F NJERAXSSDSHLGE-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- PMAHNUOELLPJRS-UHFFFAOYSA-N CN1C(=O)N(C=2N=CNC2C1=O)CC(C)C.CN1C(=O)N(C=2N=CNC2C1=O)CC(C)C Chemical compound CN1C(=O)N(C=2N=CNC2C1=O)CC(C)C.CN1C(=O)N(C=2N=CNC2C1=O)CC(C)C PMAHNUOELLPJRS-UHFFFAOYSA-N 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- OSILKTNFXJYZTB-UHFFFAOYSA-L calcium;dichlorate;dihydrate Chemical compound O.O.[Ca+2].[O-]Cl(=O)=O.[O-]Cl(=O)=O OSILKTNFXJYZTB-UHFFFAOYSA-L 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 238000012200 cell viability kit Methods 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- PKRPQASGRXWUOJ-UHFFFAOYSA-L dipotassium;dichloride Chemical compound [Cl-].[Cl-].[K+].[K+] PKRPQASGRXWUOJ-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- OKBPCTLSPGDQBO-UHFFFAOYSA-L disodium;dichloride Chemical compound [Na+].[Na+].[Cl-].[Cl-] OKBPCTLSPGDQBO-UHFFFAOYSA-L 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000004688 heptahydrates Chemical class 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229960001594 tiletamine hydrochloride Drugs 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/73—Hydrolases (EC 3.)
- C12N2501/734—Proteases (EC 3.4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2523/00—Culture process characterised by temperature
Definitions
- the present invention relates to a method for separating islets from newborn pigs, specifically (a) extracting the islets from newborn pigs; (b) injecting enzyme into the isolated pancreas; And (c) relates to a method for isolating islets of newborn pigs comprising the step of inducing the activation of the enzyme.
- pancreatic islet transplantation is a relatively simple treatment, less surgical complications, and can be transplanted repeatedly, which is particularly applicable to patients with type 1 diabetes.
- pancreatic islet transplantation is a relatively simple treatment, less surgical complications, and can be transplanted repeatedly, which is particularly applicable to patients with type 1 diabetes.
- pancreatic islets due to their rapid development and maturity, large numbers of offspring, organ size and physiological functions similar to humans, and the secretion of biologically active insulin in humans (Dufrane). et al., Transplant Rev (Orlando), 26 (3): 183-8, 2012).
- the study of the clinical application of xenograft islets to humans transplanting pig islets is considered an alternative to diabetes treatment (Samy et al., Xenotransplantation, 21 (3): 221-9, 2014).
- a technique for isolating high quality pig islets is an essential technique for xenograft transplantation, and research on this is required.
- the present inventors have diligently tried to develop an optimal pancreatic isolating technique, and as a result, it has been developed that the separation and culture and degree analysis technology of the new pig islets can be used to isolate high quality pancreatic islets with high yield.
- the present invention has been completed.
- the object of the present invention is to (a) extract the islets from the newborn pig; (b) injecting enzyme into the isolated pancreas; And (c) to provide a method for isolating islets of newborn pigs comprising the step of inducing the activation of the enzyme.
- the present invention comprises the steps of (a) extracting the islets from the newborn pig; (b) injecting enzyme into the isolated pancreas; And (c) provides a method for isolating islets of newborn pigs comprising the step of inducing the activation of the enzyme.
- pancreatic islet separation technique for cross-transplantation, as well as isolation and culture and degree of newborn pig islets.
- analytical techniques they can be widely used in biomedical fields such as diabetes treatment.
- Figure 1 shows the representative results observed after culturing the isolated NPCCs form by microscopic visual inspection for 1 day, 4 days and 7 days.
- Figure 2 shows the results of ATP activity analysis to confirm the viability of NPCCs.
- FIG. 3 shows the results of glucose-stimulated insulin secretion (GSIS) analysis to measure the insulin secretion function of NPCCs.
- GSIS glucose-stimulated insulin secretion
- the present invention relates to a method for separating high quality pancreatic islets from newborn pigs in high yield.
- the present invention in one aspect, (a) extracting the islets from the newborn pig; (b) injecting enzyme into the isolated pancreas; And (c) relates to a method for isolating islets of newborn pigs comprising the step of inducing the activation of the enzyme.
- the enzyme may be characterized in that the collagenase V (Sigma-Aldrich, MO, USA).
- the step (c) is preferably shaken in a 37 °C water bath may be characterized in that the activation of the enzyme.
- step (c) may be characterized in that it further comprises the step of culturing the islets, preferably characterized in that incubated in the presence condition of 5% carbon dioxide at 37 °C for 1 to 14 days. can do.
- F10 medium It may also be characterized by culturing in F10 medium.
- the composition of the F10 medium is shown in Table 1 below.
- the Hank balanced salt solution may be used as a buffer.
- the composition of the HBSS is shown in Table 2 below.
- Substance Tinnitus (common name) CAS number content(%) Calcium chlorate 10035-04-8 0.01 Magnesium Sulfate Nitrate Magnesium Sulphate, Heptahydrate 10034-99-8 0.001 Potassium chloride Potassium chloride 7447-40-7 0.004 Potassium phosphate monobasic Potassium Acid Phosphate 7778-77-0 0.006 Sodium chloride Sodium chloride 7647-14-5 0.8 Sodium Phosphate, Dibasic Disodium phosphate 7558-79-4 0.005 Dextrose D-glucose 50-99-7 0.1 Sodium bicarbonate Sodium bicarbonate 144-55-8 0.04 Penicillin-streptomycin, liquid 3810-74-0; 69-57-8 0.5 albumin Albuminz, Blood Serum 9048-46-8 0.25 Phenolic Red, Sodium Salt 34487-61-1 0.001 HEPES, free acid N- (2-hydroxyethyl) piperazine-N '-(2-
- the newborn pig may be characterized as being three days to five days old, but is not limited thereto.
- NPCCs Neonatal Porcine Pancreatic Cell Clusters
- Pancreatic cell clusters were isolated from 3 to 5 day old piglets (Landrace or Yorkshire), weighing approximately 1.0 to 2.0 kg. Several modifications have been made to known separation methods to isolate NPCCs (Korbutt GS et al., The Journal of clinical investigation, 97 (9): 2119-29, 1996).
- Newborn pigs were sequentially administered 0.1 mg / kg of azaferon (Stresnil, Janssen, Geneva, Belgium), 125 mg / kg of tiletamine hydrochloride, and zolazepam hydrochloride (Zoletil, Virbac, Carros, France). .
- a midline incision was used to open the newborn pigs for pancreatic exposure.
- the pancreas was carefully dissected from the surrounding pylorus, duodenum and artery. Special care has been taken to prevent bacterial infection, which may be caused by bowel nipping.
- the pancreas was cut into small pieces (1-2 mm 3 ) and Hank's balanced salt solution (Hank's) supplemented with 0.5% penicillin and streptomycin (Invitrogen, Carlsbad, USA), 0.25% bovine serum albumin (BSA) and 12.5 mM HEPES. rinsed in a balanced salt solution (HBSS).
- the tissues were then digested for exactly 11 minutes in a 37 ° C. water bath using 1.0 mg / mL collagenase V (Sigma-Aldrich, MO, USA). All the digested tissues were shaken vigorously by hand for 30 seconds until the color became milky white, and then the HBSS was added to stop the enzyme activity.
- the digested tissue was centrifuged at 450 xg for 1 minute. After resuspension, the degraded tissue was filtered through a stainless steel mesh (500 ⁇ m). The filtrate containing NPCCs was rinsed twice in HBSS. Finally, islet suspensions were supplemented with 10% adult porcine serum (APS; Gibco, Cat.No. 26250-084), 2% BSA, 0.1% ciprofloxacin and 1% penicillin and streptomycin (Ham's) F10 medium 37 Incubated in humidified air containing 5% CO 2 in the incubator. The islet islet suspension was placed in a 150 mm Petri dish for 7 days prior to the experiment. Culture medium was changed every other day. An algorithm was used to calculate 150 ⁇ m diameter pancreatic equivalent number (IEQ) (Cardona K et al., Nature medicine, 12 (3): 304-6, 2006).
- IEQ 150 ⁇ m diameter pancreatic equivalent number
- Isolated NPCCs were observed after culturing for 1, 4 and 7 days after separation using a microscope (Leica DFC 295) (FIG. 1). The average weight of the isolated islets was 1.73 ⁇ 0.45g.
- NPCCs 100 IEQ / well in 100 ⁇ l volume
- NPCCs 100 IEQ / well in 100 ⁇ l volume
- NPCCs 100 IEQ / well in 100 ⁇ l volume
- NPCCs 100 IEQ / well in 100 ⁇ l volume
- NPCCs 100 IEQ / well in 100 ⁇ l volume
- NPCCs 100 IEQ / well in 100 ⁇ l volume
- NPCCs 100 IEQ / well in 100 ⁇ l volume
- Cell Titer-Glo reagent 319
- Cells were incubated for 30 minutes at room temperature to stabilize the luminescence signal.
- Luminescence was then recorded with a luminescence counter (VICTOR TM Light, PerkinElmer, Mass., USA).
- Luminescence indicates the metabolic activity of the cell. More than 90% (18 times / 20 times) of the separated NPCCs showed more than the reference value (red dotted line in FIG. 2) of the emission value corresponding to the NPCCs 100 IEQ,
- Example 3 Of NPCCs For measuring insulin secretory response rate Glucose -Stimulated insulin secretion ( GSIS ) analysis
- NPCCs insulin secretion response rate of the isolated NPCCs
- cells were cultured for 2 weeks and then subjected to GSIS analysis.
- the isolated islets were incubated on glucose at various concentrations.
- NPCCs were suspended and pre-incubated for 30 minutes in Krebs Ringer buffered HEPES (KRBB, pH 7.4).
- NPCCs were continuously incubated in low glucose (2.5 mM) buffer and then high glucose (20 mM) buffer in humidified air containing 5% CO 2 in 37 incubators for 1 hour.
- low glucose solution 2.5 mM
- high glucose solution 20 mM
- the concentration of insulin protein secreted in the buffer was measured using the DIAsource INS-Irma kit (DIAsource ImmunoAssays SA, Louvain-la-Neuve, Belgium) (Schroff RW et al., Cancer research, 45 (2): 879-85, 1985).
- the stimulation index (SI) value was calculated by dividing the amount of insulin secreted in the high glucose solution by the amount in the low glucose solution (Jung HS, Official journal of the Controlled Release Society, 172 (3): 1092-101, 2013). As a result, it was confirmed that the range of SI values was 1 to 1.5, which indicates normal insulin secretory function in response to different glucose stimuli (FIG. 3).
- NPCCs were separated by approximately 13,000 IEQ (13,539.45 ⁇ 5182.54 IEQ) per gram of pancreatic tissue (Table 3).
- NPCCs The parameters for the separation of NPCCs are as follows: date of separation, number of newborn pigs, age of newborn pig, weight of newborn pig, weight of pancreas (time / new pig), pancreatic weight before digestion, collagenase type (Cat.No. or Lot). No.), collagenase concentration, degradation time, total cell count measured on day 7, NPCCs yield (IEQ / new pig or IEQ / pancreatic weight gram) (Table 4).
- HTK solution containing 1% penicillin-streptomycin (P / S; 10,000 U / mL) and 1% gentamycin sulfate: lL of HTK solution was obtained from the infusion packet. After ingestion, 10 ml of penicillin and streptomycin (P / S) are added, 10 ml of gentamycin sulfate is added, and the samples are subdivided into tubes every 20 ml and stored in an ice box for the extracted pancreas.
- betadine in saline To 700 ml of saline solution, 300 ml of betadine (Povidone-iodine, Mundi Pharma) is added and then subdivided into 20 ml tubes to wash the extracted pancreas.
- Penicillin and streptomycin (Gibco, Cat. No. 15140-122).
- Ketamine (Imalgenem Gellini Farma-ceutici, Aprilia, Italy).
- PAD (Cat. No. B414A003-7011).
- the leaf paper The leaf paper.
- the isolated pancreas is stored in HTK solution and placed in an ice box until the separation of NPCCs begins.
- F-10 medium (pH 7.3) containing 10% adult pig serum, 1% P / S and 0.1% ciprofloxacin (Biosesang, Cat. No. F2014).
- Collagenase type V (collagenase derived from Clostridium histories) (Sigma, Cat. No. C9263).
- Steriplip-GP Filter Unit (0.22 ⁇ m) (MILLIPORE, Cat.No. SCGP00525).
- the extracted pancreas is placed in an empty conical tube and the individual pancreas is weighed (keep the same mark).
- the suspension is then passed through a 500 ⁇ m mesh sieve, rinsing the walls of each tube and again passing 30 ml HBSS through the mesh sieve.
- NPCCs isolated from one conical tube are divided into four 150 mm Petri dishes (medium volume 35 ml).
- NPCCs are obtained from four Petri-plates with four conical tubes.
- NPCCs are obtained from four Petri-plates with four conical tubes.
- pancreatic islet separation technique for cross-transplantation, as well as isolation and culture and degree of newborn pig islets.
- analytical techniques they can be widely used in biomedical fields such as diabetes treatment.
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention relates to a method for isolating an islet from a newborn pig and, specifically, to a method for isolating an islet of a newborn pig, the method comprising the steps of: (a) extracting an islet from a newborn pig; (b) injecting an enzyme into an extracted pancreas; and (c) inducing the activation of the enzyme. The use of the method for isolating an islet according to the present invention can isolate a high-quality islet from a newborn pig at high efficiency, and thus can lead to not only the utilization as an islet isolation technique for xenotransplantation but also the development of techniques for isolation, culture, and quality analysis of an islet of a newborn pig, and therefore, the method according to the present invention can be widely utilized in the biomedical field, such as diabetes treatment.
Description
본 발명은 신생돼지로부터 췌도를 분리하는 방법에 관한 것으로, 구체적으로 (a) 신생돼지로부터 췌도를 적출하는 단계; (b) 적출한 췌장에 효소를 주입하는 단계; 및 (c) 효소의 활성화를 유도하는 단계를 포함하는 신생돼지의 췌도 분리 방법에 관한 것이다.The present invention relates to a method for separating islets from newborn pigs, specifically (a) extracting the islets from newborn pigs; (b) injecting enzyme into the isolated pancreas; And (c) relates to a method for isolating islets of newborn pigs comprising the step of inducing the activation of the enzyme.
당뇨병은 2014년에 대략 4억2천2백만 성인에 발병한 주요한 세계적인 질병이다. 1980년 이래로 그 유병률이 거의 두 배가 되었으며, 2016년 세계 당뇨병 보고서(WHO Global Diabetes Report 2016)에 따르면 성인 인구의 4.7%에서 8.5%로 증가하였다. 인슐린-의존적 당뇨병에 대한 다양한 치료법 중에서, 췌도 이식은 인슐린 의존적 당뇨병 환자에게 희망적인 치료법 중 하나로써 널리 인식되어 왔다. 췌도 이식은 시술이 비교적 간단하고 수술 합병증이 적으며 반복적으로 이식이 가능하다는 장점이 있어 특히 제1형 당뇨병 환자에게 적용할 수 있는 치료법이다. 그러나, 장기 공여자의 큰 부족으로 인해, 장기 공급과 수요의 균형이 맞지 않는 실정이다.Diabetes is a leading global disease that affects about 422 million adults in 2014. Since 1980, the prevalence has nearly doubled, rising from 4.7% to 8.5% of the adult population, according to the 2016 WHO Global Diabetes Report 2016. Among various therapies for insulin-dependent diabetes, pancreatic islet transplantation has been widely recognized as one of the promising therapies for insulin-dependent diabetes patients. Pancreatic islet transplantation is a relatively simple treatment, less surgical complications, and can be transplanted repeatedly, which is particularly applicable to patients with type 1 diabetes. However, due to the large shortage of long-term donors, long-term supply and demand are not balanced.
한편, 돼지는 발달 및 성숙이 빠르고 많은 수의 자손을 가지며 장기의 크기와 생리학적인 기능이 인간과 유사하고, 인간에서 생물학적인 활성을 지니는 인슐린을 분비하기 때문에 아주 이상적인 췌도의 공급원으로 여겨지고 있다(Dufrane et al., Transplant Rev (Orlando), 26(3):183-8, 2012). 따라서, 돼지의 췌도를 인간에게 이식하는 이종 췌도의 임상적 적용에 대한 연구가 당뇨병 치료의 대안으로 여겨지고 있다(Samy et al., Xenotransplantation, 21(3):221-9, 2014).On the other hand, pigs are considered an ideal source of pancreatic islets due to their rapid development and maturity, large numbers of offspring, organ size and physiological functions similar to humans, and the secretion of biologically active insulin in humans (Dufrane). et al., Transplant Rev (Orlando), 26 (3): 183-8, 2012). Thus, the study of the clinical application of xenograft islets to humans transplanting pig islets is considered an alternative to diabetes treatment (Samy et al., Xenotransplantation, 21 (3): 221-9, 2014).
1997년 딘스모어(Dinsmore) 등은 태아 돼지의 췌도를 분리하는 기술을 확립하고자 분리 과정에서 사용되는 효소의 종류에 따른 췌도의 분리 효율과 인슐린을 발현하는 기능에 있어서 차이가 있는지 여부를 확인한바 있고(US 5629194B2), 코르부트(Korbutt) 등은 태아 돼지 췌도 세포 응집체(aggregates)를 분리하여 시험관내에서 9일간 배양한 후에 당뇨병 모델의 마우스의 신피막하에 이식하여 혈당 조절 기능을 하는 것을 보고한 바 있으며(Korbutt GS et al., The Journal of clinical investigation, 97(9):2119-29, 1996), 램브(Lamb) 등은 평균 20일령의 돼지를 사용하여 췌도를 분리하고 정도 분석을 수행한 결과를 보고한 바 있다(M. Lamb et al., Cell transplantation, 23(3):263-72, 2014).In 1997, Dinsmore et al. Identified whether there is a difference in the separation efficiency of pancreatic islets and the function of expressing insulin according to the types of enzymes used in the isolation process to establish a technique for isolating fetal islets. (US 5629194B2), Korbutt et al. Reported that fetal pig islet cell aggregates were isolated and cultured in vitro for 9 days before transplanting under the neocapillary membrane of diabetic mice to regulate blood glucose control. (Korbutt GS et al., The Journal of clinical investigation, 97 (9): 2119-29, 1996), and Lamb et al. Used an average 20-day-old pig to isolate the pancreatic islets and perform a degree analysis. (M. Lamb et al., Cell transplantation, 23 (3): 263-72, 2014).
이와 같이, 양질의 돼지 췌도를 분리하는 기술은 이종 췌도 이식을 위해 필수적인 제반 기술로서, 이에 대한 연구가 요구되고 있는 실정이다.As such, a technique for isolating high quality pig islets is an essential technique for xenograft transplantation, and research on this is required.
이에, 본 발명자들은 최적의 췌도 분리 기술을 개발하고자 예의 노력한 결과, 신생돼지 췌도의 분리와 배양 및 정도 분석 기술을 개발하고, 이를 이용하면 높은 수율로 양질의 췌도를 분리할 수 있음을 확인하여, 본 발명을 완성하게 되었다.Therefore, the present inventors have diligently tried to develop an optimal pancreatic isolating technique, and as a result, it has been developed that the separation and culture and degree analysis technology of the new pig islets can be used to isolate high quality pancreatic islets with high yield. The present invention has been completed.
본 발명의 목적은 (a) 신생돼지로부터 췌도를 적출하는 단계; (b) 적출한 췌장에 효소를 주입하는 단계; 및 (c) 효소의 활성화를 유도하는 단계를 포함하는 신생돼지의 췌도 분리 방법을 제공하는데 있다.The object of the present invention is to (a) extract the islets from the newborn pig; (b) injecting enzyme into the isolated pancreas; And (c) to provide a method for isolating islets of newborn pigs comprising the step of inducing the activation of the enzyme.
상기 목적을 달성하기 위하여, 본 발명은 (a) 신생돼지로부터 췌도를 적출하는 단계; (b) 적출한 췌장에 효소를 주입하는 단계; 및 (c) 효소의 활성화를 유도하는 단계를 포함하는 신생돼지의 췌도 분리 방법을 제공한다.In order to achieve the above object, the present invention comprises the steps of (a) extracting the islets from the newborn pig; (b) injecting enzyme into the isolated pancreas; And (c) provides a method for isolating islets of newborn pigs comprising the step of inducing the activation of the enzyme.
본 발명에 따른 췌도의 분리 방법을 이용하면 신생돼지로부터 높은 효율로 양질의 췌도를 분리해낼 수 있는바, 이종간 이식을 위한 췌도 분리 기술로서 활용할 수 있을 뿐만 아니라, 신생돼지 췌도의 분리와 배양 및 정도 분석 기술을 개발함으로써, 당뇨병 치료 등 생명의학 분야에서 널리 활용될 수 있다.Using the method for isolating islets according to the present invention can separate high-quality pancreatic islets from newborn pigs with high efficiency, and can be used as a pancreatic islet separation technique for cross-transplantation, as well as isolation and culture and degree of newborn pig islets. By developing analytical techniques, they can be widely used in biomedical fields such as diabetes treatment.
도 1은 분리된 NPCCs 형태를 현미경 육안 검사를 통해 분리 후 1일, 4일 및 7일 동안 배양한 후 관찰한 대표적인 연구 결과를 나타낸 것이다.Figure 1 shows the representative results observed after culturing the isolated NPCCs form by microscopic visual inspection for 1 day, 4 days and 7 days.
도 2는 NPCCs의 생존능을 확인하기 위한 ATP 활성 분석 결과를 나타낸 것이다.Figure 2 shows the results of ATP activity analysis to confirm the viability of NPCCs.
도 3은 NPCCs의 인슐린 분비 기능을 측정하기 위한 글루코스-자극 인슐린 분비(GSIS) 분석 결과를 나타낸 것이다.Figure 3 shows the results of glucose-stimulated insulin secretion (GSIS) analysis to measure the insulin secretion function of NPCCs.
도 4는 NPCCs 수 계산 차트이다.4 is a NPCCs number calculation chart.
다른 식으로 정의되지 않는 한, 본 명세서에서 사용된 모든 기술적 및 과학적 용어들은 본 발명이 속하는 기술 분야에서 숙련된 전문가에 의해서 통상적으로 이해되는 것과 동일한 의미를 가진다. 일반적으로, 본 명세서에서 사용된 명명법은 본 기술 분야에서 잘 알려져 있고 통상적으로 사용되는 것이다.Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In general, the nomenclature used herein is well known and commonly used in the art.
본 발명은 신생돼지로부터 높은 수율로 양질의 췌도를 분리하는 방법에 관한 것이다.The present invention relates to a method for separating high quality pancreatic islets from newborn pigs in high yield.
본 발명은 일 관점에서, (a) 신생돼지로부터 췌도를 적출하는 단계; (b) 적출한 췌장에 효소를 주입하는 단계; 및 (c) 효소의 활성화를 유도하는 단계를 포함하는 신생돼지의 췌도 분리 방법에 관한 것이다.The present invention in one aspect, (a) extracting the islets from the newborn pig; (b) injecting enzyme into the isolated pancreas; And (c) relates to a method for isolating islets of newborn pigs comprising the step of inducing the activation of the enzyme.
본 발명에 있어서, 상기 효소는 콜라게나아제 V(시그마-알드리치, MO, USA)인 것을 특징으로 할 수 있다.In the present invention, the enzyme may be characterized in that the collagenase V (Sigma-Aldrich, MO, USA).
본 발명에 있어서, 상기 (c) 단계는 바람직하게는 37℃ 수조에서 흔들어 효소의 활성화를 유도하는 것을 특징으로 할 수 있다.In the present invention, the step (c) is preferably shaken in a 37 ℃ water bath may be characterized in that the activation of the enzyme.
본 발명에 있어서, 상기 (c) 단계 후에 췌도를 배양하는 단계를 더 포함하는 것을 특징으로 할 수 있고, 바람직하게는 1일 내지 14일 동안 37℃에서 5% 이산화탄소 존재 조건하에서 배양하는 것을 특징으로 할 수 있다. In the present invention, after the step (c) may be characterized in that it further comprises the step of culturing the islets, preferably characterized in that incubated in the presence condition of 5% carbon dioxide at 37 ℃ for 1 to 14 days. can do.
또한, F10 배지에서 배양하는 것을 특징으로 할 수 있다. F10 배지의 조성은 하기 표 1과 같다.It may also be characterized by culturing in F10 medium. The composition of the F10 medium is shown in Table 1 below.
물질명Substance | 이명(관용명)Tinnitus (common name) | CAS 번호CAS number | 함유량(%)content(%) |
Nutrient Mixture F-10 HamNutrient Mixture F-10 Ham | Ham's F-10Ham's F-10 | 8787 | |
이탄산 나트륨Sodium bicarbonate | 탄산수소 나트륨Sodium bicarbonate | 144-55-8144-55-8 | 0.10.1 |
니코틴아마이드Nicotinamide | 니코틴산 아마이드: 비타민 B3Niacinamide: Vitamin B3 | 98-92-098-92-0 | 0.10.1 |
덱스트로스Dextrose | D-포도당D-glucose | 50-99-750-99-7 | 0.070.07 |
L-(+)-글루타민L-(+)-Glutamine | 2-아미노글루타라믹산2-aminoglutamic acid | 56-85-956-85-9 | 0.010.01 |
염소산 칼슘, 이수화물Calcium chlorate, dihydrate | 염소산 칼슘(Ⅱ), 염소산 칼슘, E509Calcium chlorate (II), calcium chlorate, E509 | 10035-04-810035-04-8 | 0.020.02 |
알부민albumin | 알부민즈, 블러드 세룸Albuminz, Blood Serum | 9048-46-89048-46-8 | 22 |
3-이소부틸-1-메틸잔틴3-isobutyl-1-methylxanthine | 3-이소부틸-1-메틸-2,6(1H,3H)-퓨린디온3-isobutyl-1-methyl-2,6 (1H, 3H) -purindione | 28822-58-428822-58-4 | 0.0010.001 |
페니실린-스트렙토마이신, 액체Penicillin-streptomycin, liquid | 3810-74-0; 69-57-83810-74-0; 69-57-8 | 1One | |
시프로플록사신Ciprofloxacin | 시프로바이Ciproby | 85721-33-185721-33-1 | 0.0020.002 |
돼지 혈청 |
1010 |
본 발명에 있어서, 행크 평형 염류 용액을 완충액으로 사용하는 것을 특징으로 할 수 있다. HBSS의 조성은 하기 표 2와 같다.In the present invention, the Hank balanced salt solution may be used as a buffer. The composition of the HBSS is shown in Table 2 below.
물질명Substance | 이명(관용명)Tinnitus (common name) | CAS 번호CAS number | 함유량(%)content(%) |
염소산 칼슘Calcium chlorate | 10035-04-810035-04-8 | 0.010.01 | |
황산 마그네슘 질수화물Magnesium Sulfate Nitrate | 마그네슘 황산염, 헵타수화물Magnesium Sulphate, Heptahydrate | 10034-99-810034-99-8 | 0.0010.001 |
염화칼륨Potassium chloride | 칼륨 염화물Potassium chloride | 7447-40-77447-40-7 | 0.0040.004 |
인산 칼륨 일염기성Potassium phosphate monobasic | 칼륨 산 인산염Potassium Acid Phosphate | 7778-77-07778-77-0 | 0.0060.006 |
염화 나트륨Sodium chloride | 염화 나트륨Sodium chloride | 7647-14-57647-14-5 | 0.80.8 |
인산 나트륨, 이염기Sodium Phosphate, Dibasic | 인산 이나트륨Disodium phosphate | 7558-79-47558-79-4 | 0.0050.005 |
덱스트로스Dextrose | D-포도당D-glucose | 50-99-750-99-7 | 0.10.1 |
이탄산 나트륨Sodium bicarbonate | 탄산수소 나트륨Sodium bicarbonate | 144-55-8144-55-8 | 0.040.04 |
페니실린-스트렙토마이신, 액체Penicillin-streptomycin, liquid | 3810-74-0; 69-57-83810-74-0; 69-57-8 | 0.50.5 | |
알부민albumin | 알부민즈, 블러드 세룸Albuminz, Blood Serum | 9048-46-89048-46-8 | 0.250.25 |
페놀 레드, 나트륨염Phenolic Red, Sodium Salt | 34487-61-134487-61-1 | 0.0010.001 | |
HEPES, 유리산HEPES, free acid | N-(2-하이드록시에틸)피페라진-N'-(2-에탄술폰산)N- (2-hydroxyethyl) piperazine-N '-(2-ethanesulfonic acid) | 7365-45-97365-45-9 |
본 발명에 있어서, 신생돼지는 생후 3일 내지 5일 된 것을 특징으로 할 수 있으나, 이에 한정되는 것은 아니다.In the present invention, the newborn pig may be characterized as being three days to five days old, but is not limited thereto.
[실시예]EXAMPLE
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다. 따라서 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention, and it will be apparent to those skilled in the art that the scope of the present invention is not to be construed as being limited by these examples. Thus, the substantial scope of the present invention will be defined by the appended claims and their equivalents.
실시예 1: 신생돼지 췌장 세포 클러스터(NPCCs)의 분리 및 확인Example 1: Isolation and Identification of Neonatal Porcine Pancreatic Cell Clusters (NPCCs)
대략 체중이 1.0 내지 2.0 kg인, 3일 내지 5일 령의 신생돼지(Landrace 또는 Yorkshire)로부터 췌장 세포 클러스터를 분리하였다. 이미 알려진 분리 방법에 몇 가지 변형을 가하여 NPCCs를 분리하였다(Korbutt GS et al., The Journal of clinical investigation, 97(9):2119-29, 1996). Pancreatic cell clusters were isolated from 3 to 5 day old piglets (Landrace or Yorkshire), weighing approximately 1.0 to 2.0 kg. Several modifications have been made to known separation methods to isolate NPCCs (Korbutt GS et al., The Journal of clinical investigation, 97 (9): 2119-29, 1996).
신생돼지에 순차적으로 0.1 mg/kg의 아자페론(Stresnil, Janssen, Bruxelles, Belgium), 125 mg/kg의 틸레타민 염산염, 및 졸라제팜 염산염(Zoletil, Virbac, Carros, France)을 근육내 투여하였다. 췌장 노출을 위해 정중선 절개로 신생돼지에 개복술을 하였다. 췌장을 주변 유문, 십이지장 및 동맥으로부터 조심스럽게 해부하였다. 창자 해침(bowel nipping)에 의해 유발될 수 있는, 박테리아 감염을 방지하기 위하여 특별한 주의를 기울였다. 췌장을 작은 조각(1 내지 2 mm3)으로 자르고, 0.5% 페니실린 및 스트렙토마이신(Invitrogen, Carlsbad, USA), 0.25% 소혈청 알부민(BSA) 및 12.5 mM HEPES가 보충된, 행크 평형 염류 용액(Hank's balanced salt solution; HBSS)에서 헹구었다. 그 후 조직을 1.0 mg/mL의 콜라게나아제 V(시그마-알드리치, MO, USA)를 이용하여 37℃ 수조에서 정확히 11분 동안 분해시켰다. 분해된 모든 조직을 색이 우윳빛 흰색이 될 때까지 30초 동안 손으로 강하게 흔들고, 그 다음 상기 HBSS를 효소 활성을 멈추기 위하여 첨가하였다. 분해된 조직을 1분 동안 450 x g에서 원심분리하였다. 재부유 후에 분해된 조직을 스테인리스 스틸 메쉬(500 μm)를 통해 여과하였다. NPCCs를 함유하는 여과액을 HBSS에서 두 번 헹구었다. 마지막으로, 췌도 현탁액을 10% 성체 돼지 혈청(APS; Gibco, Cat. No. 26250-084), 2% BSA, 0.1% 시프로플록사신 및 1% 페니실린 및 스트렙토마이신이 보충된 함(Ham's) F10 배지 내 37℃ 배양기에서 5% CO2를 함유하는 가습된 공기에서 배양하였다. 췌도 현탁액을 실험에 앞서 7일 동안 150 mm 페트리 접시에 두었다. 배양 배지를 격일로 바꾸었다. 150 μm 직경 췌도 당량수(IEQ)를 계산하는데 알고리즘을 사용하였다(Cardona K et al., Nature medicine, 12(3):304-6, 2006). Newborn pigs were sequentially administered 0.1 mg / kg of azaferon (Stresnil, Janssen, Bruxelles, Belgium), 125 mg / kg of tiletamine hydrochloride, and zolazepam hydrochloride (Zoletil, Virbac, Carros, France). . A midline incision was used to open the newborn pigs for pancreatic exposure. The pancreas was carefully dissected from the surrounding pylorus, duodenum and artery. Special care has been taken to prevent bacterial infection, which may be caused by bowel nipping. The pancreas was cut into small pieces (1-2 mm 3 ) and Hank's balanced salt solution (Hank's) supplemented with 0.5% penicillin and streptomycin (Invitrogen, Carlsbad, USA), 0.25% bovine serum albumin (BSA) and 12.5 mM HEPES. rinsed in a balanced salt solution (HBSS). The tissues were then digested for exactly 11 minutes in a 37 ° C. water bath using 1.0 mg / mL collagenase V (Sigma-Aldrich, MO, USA). All the digested tissues were shaken vigorously by hand for 30 seconds until the color became milky white, and then the HBSS was added to stop the enzyme activity. The digested tissue was centrifuged at 450 xg for 1 minute. After resuspension, the degraded tissue was filtered through a stainless steel mesh (500 μm). The filtrate containing NPCCs was rinsed twice in HBSS. Finally, islet suspensions were supplemented with 10% adult porcine serum (APS; Gibco, Cat.No. 26250-084), 2% BSA, 0.1% ciprofloxacin and 1% penicillin and streptomycin (Ham's) F10 medium 37 Incubated in humidified air containing 5% CO 2 in the incubator. The islet islet suspension was placed in a 150 mm Petri dish for 7 days prior to the experiment. Culture medium was changed every other day. An algorithm was used to calculate 150 μm diameter pancreatic equivalent number (IEQ) (Cardona K et al., Nature medicine, 12 (3): 304-6, 2006).
분리된 NPCCs 형태를 현미경(Leica DFC 295)를 사용하여 분리 후 1일, 4일 및 7일 동안 배양한 후에 관찰하였다(도 1). 적출된 췌도의 무게는 평균 1.73±0.45g이었다.Isolated NPCCs were observed after culturing for 1, 4 and 7 days after separation using a microscope (Leica DFC 295) (FIG. 1). The average weight of the isolated islets was 1.73 ± 0.45g.
동물 사용에 대한 프로토콜은 서울대학교의 실험동물 보호 및 이용을 위한 지침에 따라 서울대학교 실험동물운영위원회(SNU-151103-1)의 승인을 받았다.The protocol for animal use was approved by the Seoul National University Laboratory Animal Steering Committee (SNU-151103-1) in accordance with Seoul National University's Guidelines for the Protection and Use of Laboratory Animals.
실시예 2: NPCCs 생존능 확인을 위한 ATP 활성 분석Example 2: ATP Activity Assay for Confirmation of NPCCs Viability
세포내 ATP의 측정이 췌도 세포의 물질대사 기능을 포함하여, 간단하고 신뢰성 있는 세포 생존능의 지표로 증명되었다(Ishii S et al., Transplantation proceedings, 37(8):3499-500, 2005). 7일된 배양물 내 ATP의 정량 평가에 의해 세포 생존능 분석을 수행하였다. Measurement of intracellular ATP has been demonstrated as a simple and reliable indicator of cell viability, including metabolic function of islet cells (Ishii S et al., Transplantation proceedings, 37 (8): 3499-500, 2005). Cell viability assays were performed by quantitative assessment of ATP in 7-day cultures.
발광 세포 생존능 분석 키트(Promega Corporation, Madison, USA)를 이용하여 세포 생존능을 정량 분석하였다. NPCCs(100 μl 부피 내 100 IEQ/웰)를 96-웰 플레이트에 두고, 플레이트와 그 내용물을 미리 꺼내두어 실온으로 맞추었다. 세포 용해를 유도하기 위하여, 동일한 부피의 셀 타이터-글로 시약(Cell Titer-Glo reagent, 39)을 첨가하여 2분 동안 혼합하였다. 발광 신호를 안정화시키기 위하여 세포를 실온에서 30분 동안 배양하였다. 그 다음 발광 카운터(VICTORTM Light, PerkinElmer, MA, USA)로 발광을 기록하였다. 발광값은 세포의 대사 활성을 나타낸다. 분리된 NPCCs 중 90% 이상(18회/20회)에서 NPCCs 100 IEQ에 해당되는 발광값의 참고치(도 2의 붉은 점선) 이상을 나타냄으로써 정상적인 물질대사에 의한 생존능을 확인할 수 있었다(도 2).Cell viability was quantitated using the Luminescent Cell Viability Assay Kit (Promega Corporation, Madison, USA). NPCCs (100 IEQ / well in 100 μl volume) were placed in 96-well plates and the plates and their contents were taken out beforehand to room temperature. To induce cell lysis, equal volumes of Cell Titer-Glo reagent (39) were added and mixed for 2 minutes. Cells were incubated for 30 minutes at room temperature to stabilize the luminescence signal. Luminescence was then recorded with a luminescence counter (VICTOR ™ Light, PerkinElmer, Mass., USA). Luminescence indicates the metabolic activity of the cell. More than 90% (18 times / 20 times) of the separated NPCCs showed more than the reference value (red dotted line in FIG. 2) of the emission value corresponding to the NPCCs 100 IEQ, thereby confirming the viability of normal metabolism (FIG. 2). .
실시예Example
3: 3:
NPCCs의Of NPCCs
인슐린 분비 반응 속도 측정을 위한 For measuring insulin secretory response rate
글루코스Glucose
-자극 인슐린 분비(-Stimulated insulin secretion (
GSISGSIS
) 분석) analysis
분리된 NPCCs의 인슐린 분비 반응 속도를 측정하기 위하여, 세포를 2주 동안 배양한 후 GSIS 분석을 수행하였다. 분리된 췌도를 다양한 농도의 글루코스 상에서 배양하였다. NPCCs를 부유시키고, 크렙 링어 완충 HEPES(Krebs Ringer buffered HEPES; KRBB, pH 7.4)에서 30분 동안 전-배양하였다. NPCCs를 1시간 동안 37 배양기에서 5% CO2를 함유하는 가습된 공기 내에서 저 글루코스(2.5 mM) 완충액, 다음 고 글루코스(20 mM) 완충액에서 연속적으로 배양하였다. 분리된 NPCCs가 저글루코스 용액(2.5 mM) 또는 고글루코스 용액(20 mM)에서 1시간 동안 연속적으로 배양되었을 때, 인슐린 분비 패턴이 매우 유사하였다. 최종적으로, 완충액 내 분비된 인슐린 단백질의 농도를 DIAsource INS-Irma kit(DIAsource ImmunoAssays SA, Louvain-la-Neuve, Belgium)를 이용하여 측정하였다(Schroff RW et al., Cancer research, 45(2):879-85, 1985). 자극 지수(SI) 값을 고 글루코스 용액 내 분비된 인슐린의 양을 저 글루코스 용액 내 양으로 나누어 계산하였다(Jung HS, Official journal of the Controlled Release Society, 172(3):1092-101, 2013). 그 결과 SI 수치의 범위가 1 내지 1.5임을 확인하였고, 이는 서로 다른 글루코스 자극에 반응하여 정상적인 인슐린 분비 기능을 가지는 것을 나타낸다(도 3).In order to measure the insulin secretion response rate of the isolated NPCCs, cells were cultured for 2 weeks and then subjected to GSIS analysis. The isolated islets were incubated on glucose at various concentrations. NPCCs were suspended and pre-incubated for 30 minutes in Krebs Ringer buffered HEPES (KRBB, pH 7.4). NPCCs were continuously incubated in low glucose (2.5 mM) buffer and then high glucose (20 mM) buffer in humidified air containing 5% CO 2 in 37 incubators for 1 hour. When isolated NPCCs were continuously incubated for 1 hour in a low glucose solution (2.5 mM) or high glucose solution (20 mM), the insulin secretion pattern was very similar. Finally, the concentration of insulin protein secreted in the buffer was measured using the DIAsource INS-Irma kit (DIAsource ImmunoAssays SA, Louvain-la-Neuve, Belgium) (Schroff RW et al., Cancer research, 45 (2): 879-85, 1985). The stimulation index (SI) value was calculated by dividing the amount of insulin secreted in the high glucose solution by the amount in the low glucose solution (Jung HS, Official journal of the Controlled Release Society, 172 (3): 1092-101, 2013). As a result, it was confirmed that the range of SI values was 1 to 1.5, which indicates normal insulin secretory function in response to different glucose stimuli (FIG. 3).
실시예 4: NPCCs 분리 수율의 확인Example 4 Confirmation of NPCCs Separation Yield
분리된 NPCCs를 7일간 배양한 후, NPCCs의 분리 수율을 확인하였다. 췌장 조직 그람 당 대략 13,000 IEQ(13,539.45±5182.54 IEQ) 이상으로 NPCCs가 분리될 수 있음을 확인하였다(표 3).After incubating the isolated NPCCs for 7 days, the separation yield of NPCCs was confirmed. It was confirmed that NPCCs could be separated by approximately 13,000 IEQ (13,539.45 ± 5182.54 IEQ) per gram of pancreatic tissue (Table 3).
[표 3]TABLE 3
실시예Example
5: 신생돼지 5: newborn pig
췌도의Pancreatic islet
분리와 배양 및 정도 분석 방법에 대한 표준작업지침(Standard Operating Procedures, SOP)의 확립 Establishment of Standard Operating Procedures (SOPs) for Separation, Culture and Quality Analysis Methods
5-1: 5-1:
NPCCsNPCCs
분리를 위한 파라미터 Parameters for Separation
NPCCs 분리를 위한 파라미터는 다음과 같다: 분리 일자, 신생돼지 수, 신생돼지 나이, 신생돼지 체중, 췌장 적출(시간/신생돼지), 분해 전 췌장 무게, 콜라게나아제 종류(Cat. No. 또는 Lot. No.), 콜라게나아제 농도, 분해 시간, 7일 차에 측정된 총 세포수, NPCCs 수율(IEQ/신생돼지 또는 IEQ/췌장 무게 그람)(표 4).The parameters for the separation of NPCCs are as follows: date of separation, number of newborn pigs, age of newborn pig, weight of newborn pig, weight of pancreas (time / new pig), pancreatic weight before digestion, collagenase type (Cat.No. or Lot). No.), collagenase concentration, degradation time, total cell count measured on day 7, NPCCs yield (IEQ / new pig or IEQ / pancreatic weight gram) (Table 4).
[표 4]TABLE 4
5-2: 췌장 적출5-2: Pancreas Extraction
5-2-1: 재료5-2-1: Material
1% 페니실린-스트렙토마이신(P/S; 10,000 U/mL) 및 1% 젠타마이신 황산염을 함유하는 HTK 용액: 인퓨전 패킷으로부터 lL의 HTK 용액(Dr. Frank Kohler Chemie GmbH, Cat. No. D64625)를 취한 후, 10 ml의 페니실린 및 스트렙토마이신(P/S)을 첨가하고, 10ml의 젠타마이신 황산염을 첨가한 후, 시료를 20ml씩 튜브에 소분하고 적출된 췌장을 위한 아이스박스에 보관한다.HTK solution containing 1% penicillin-streptomycin (P / S; 10,000 U / mL) and 1% gentamycin sulfate: lL of HTK solution (Dr. Frank Kohler Chemie GmbH, Cat. No. D64625) was obtained from the infusion packet. After ingestion, 10 ml of penicillin and streptomycin (P / S) are added, 10 ml of gentamycin sulfate is added, and the samples are subdivided into tubes every 20 ml and stored in an ice box for the extracted pancreas.
염류 용액(saline) 내 30% 베타딘: 700ml의 염류 용액에, 300ml의 베타딘(포비돈-아이오딘, Mundi Pharma)을 첨가한 후, 적출된 췌장을 씻기 위하여 20ml 튜브에 소분한다.30% betadine in saline: To 700 ml of saline solution, 300 ml of betadine (Povidone-iodine, Mundi Pharma) is added and then subdivided into 20 ml tubes to wash the extracted pancreas.
적출된 췌장을 씻기 위하여 일반 염류 용액을 소분(20ml/ 튜브).Subdivide the normal salt solution (20ml / tube) to wash the extracted pancreas.
페니실린 및 스트렙토마이신(Gibco, Cat. No. 15140-122).Penicillin and streptomycin (Gibco, Cat. No. 15140-122).
젠타마이신 황산염(Biowest, Cat. No. L0011-100).Gentamycin sulfate (Biowest, Cat. No. L0011-100).
K-40(JW Pharmacuticals, Cat. No. 13011).K-40 (JW Pharmacuticals, Cat. No. 13011).
스크럽(베라틴 스크럽, Dongin dang Pharmaceutical Co., Ltd.).Scrub (veratin scrub, Dongin dang Pharmaceutical Co., Ltd.).
케타민(Imalgenem Gellini Farma-ceutici, Aprilia, Italy).Ketamine (Imalgenem Gellini Farma-ceutici, Aprilia, Italy).
스트레스닐(Janssen Pharmaceuticals, Cat. No. CAB0800).Stressil (Janssen Pharmaceuticals, Cat.No. CAB0800).
PAD(Cat. No. B414A003-7011).PAD (Cat. No. B414A003-7011).
수술 가운(DOWOO, KM Healthcare Corporation Ltd., GWN-102).Surgical gown (DOWOO, KM Healthcare Corporation Ltd., GWN-102).
하프 시트(DOWOO, KM Healthcare Corporation Ltd., WRD-1118).Half sheet (DOWOO, KM Healthcare Corporation Ltd., WRD-1118).
수술 장비 세트Surgical equipment set
스테릴 가제(Dae Han medical Supply Co. Ltd., Cat. No. GST315002).Steril gauze (Dae Han medical Supply Co. Ltd., Cat.No. GST315002).
수술 장갑(Cardincal Health, Cat. No. 2D7203I).Surgical Gloves (Cardincal Health, Cat.No. 2D7203I).
일반 손 장갑(Complete Care Plus).General Hand Gloves (Complete Care Plus).
50ml 코니칼 튜브(Greenpia Techinology, Cat. No. 50050).50 ml conical tubes (Greenpia Techinology, Cat. No. 50050).
주사기(1ml, 3ml, 및 30ml)(Korea Vaccine Co. Ltd.).Syringes (1 ml, 3 ml, and 30 ml) from Korea Vaccine Co. Ltd.
수술용 칼(Feather Disposable Sterile Surgical Blades, No. 20).Surgical knife (Feather Disposable Sterile Surgical Blades, No. 20).
바늘(17G)(Korea vaccine Co. Ltd.)Needle (17G) (Korea vaccine Co. Ltd.)
70% 에탄올(Duksan, Cat. No. 64-17-5).70% ethanol (Duksan, Cat. No. 64-17-5).
박엽지.The leaf paper.
5-2-2: 과정5-2-2: Course
1. 우선, 수술 구역을 정비한다.1. First, repair the surgery area.
2. 희생 전에 근육(팔 하부) 내로 마취제를 주입한다(0.1mg/kg의 스트레스닐(아자페론) 및 15mg/kg의 케타민).2. Inject anesthetic into the muscle (lower arm) before sacrifice (0.1 mg / kg of stressil (azaferon) and 15 mg / kg of ketamine).
3. 체중을 측정하고 기록한다.3. Measure and record your weight.
4. 수돗물로 신생돼지 몸체를 씻은 후 70% 에탄올을 뿌리고 박엽지로 닦는다.4. Wash the new pig body with tap water, sprinkle 70% ethanol and wipe it with thin paper.
5. 심장에 구멍을 내어 혈액을 수득한다.5. Puncture the heart to obtain blood.
6. 동일한 경로로 K-40을 심장으로 주입한다(약 3ml).6. Inject K-40 into the heart via the same route (approximately 3 ml).
7. 스크럽으로 전체 몸체를 닦는다.7. Clean the entire body with a scrub.
8. 신생돼지 복부를 절개한다.8. Incision in newborn pig abdomen.
9. 췌장을 적출한다(스테릴 가제 및 손가락 이용). 그 후 췌장의 무게를 측정한다.9. Extract the pancreas (using steryl gauze and fingers). The pancreas is then weighed.
10. 30% 베타딘 용액에 살짝 담그고 즉시 염수로 씻는다.10. Lightly soak in 30% betadine solution and immediately wash with brine.
11. 적출한 췌장은 HTK 용액에 저장하고, NPCCs 분리를 시작할 때까지 아이스박스에 넣어 둔다.11. The isolated pancreas is stored in HTK solution and placed in an ice box until the separation of NPCCs begins.
5-3: NPCCs 분리5-3: NPCCs Separation
5-3-1: 재료5-3-1: Material
0.25% BSA, 0.5% P/S를 함유하는 행크 평형 염류 용액(pH 7.35) (Biosesang, Cat. No. H2074).Hank's balanced salt solution (pH 7.35) containing 0.25% BSA, 0.5% P / S (Biosesang, Cat. No. H2074).
10% 성체 돼지 혈청, 1% P/S 및 0.1% 시프로플록사신을 함유하는 F-10 배지(pH 7.3)(Biosesang, Cat. No. F2014).F-10 medium (pH 7.3) containing 10% adult pig serum, 1% P / S and 0.1% ciprofloxacin (Biosesang, Cat. No. F2014).
콜라게나아제 타입 V(클로스트리듐 히스토리티굼 유래 콜라게나아제)(Sigma, Cat. No. C9263).Collagenase type V (collagenase derived from Clostridium histories) (Sigma, Cat. No. C9263).
겸자 및 가위(오토클레이브).Forceps and scissors (autoclave).
500 μm 메쉬 체.500 μm mesh sieve.
스테리플립-GP 필터 유닛(0.22μm)(MILLIPORE, Cat. No. SCGP00525).Steriplip-GP Filter Unit (0.22μm) (MILLIPORE, Cat.No. SCGP00525).
50ml 코니칼 튜브.50 ml conical tubes.
알코올 램프.Alcohol lamp.
10ml 및 25ml 피펫 및 피펫-에이드.10 ml and 25 ml pipettes and pipette-aids.
5-3-2: 과정5-3-2: Course
1. F-10 배지 및 HBSS를 37℃ 항온수조에 담가둔다.1. Soak F-10 medium and HBSS in 37 ℃ constant temperature water bath.
2. 상기 5-5-2 과정에서 적출된 췌장을 준비한다.2. Prepare the pancreas extracted in step 5-5-2.
3. NPCCs 분리를 위해 무균 실험대를 세팅한다(소분: HBSS, 100% 에탄올, 알코올 램프를 켠다).3. Set up a sterile bench to isolate NPCCs (subsection: turn on HBSS, 100% ethanol, alcohol lamp).
4. 소분 HBSS 튜브에 멸균한 핀셋을 넣는다.4. Place the sterilized tweezers into a small HBSS tube.
5. 적출된 췌장을 빈 코니칼 튜브에 넣고, 개체별 췌장의 무게를 측정한다(동일한 표시로 유지함).5. The extracted pancreas is placed in an empty conical tube and the individual pancreas is weighed (keep the same mark).
6. 각각의 튜브에 15ml의 HBSS를 첨가한다(1 그람 췌장 당).6. Add 15 ml of HBSS to each tube (per 1 gram pancreas).
7. 튜브 안에서 30초 동안 연속으로 가위질을 하여 작은 덩어리로 만들어 준 후, HBSS를 첨가하여 부피를 50ml로 조정하고 사용한 가위는 100% 에탄올에 살짝 담근 다음 알코올 램프에 건조시키고 HBSS에 살짝 담근 후 다시 사용하는 것과 같이, 가위를 매번 소독한다.7. Scissor continuously in a tube for 30 seconds to form a small mass. Adjust the volume to 50 ml by adding HBSS. Slightly use the scissors in 100% ethanol, dry in an alcohol lamp, lightly soak in HBSS and then again. As used, disinfect the scissors every time.
8. 원심분리한다(1500 rpm, 1분).8. Centrifuge (1500 rpm, 1 min).
9. 세포 펠렛까지 상청액을 버린다.9. Discard the supernatant up to the cell pellet.
10. 콜라게나아제 용액(1mg/ml)을 준비하고, 0.22μm 필터로 여과하고, 준비된 콜라게나아제 용액 25ml을 잘라진 췌장에 섞는다(25ml 콜라게나아제 용액/ 1 그람 당량 췌장).10. Prepare collagenase solution (1 mg / ml), filter with a 0.22 μm filter and mix 25 ml of the prepared collagenase solution to the cut pancreas (25 ml collagenase solution / 1 gram equivalent of pancreas).
11. 각각의 효소 및 췌장이 담긴 코니칼 튜브의 뚜껑을 봉한 다음 37℃ 쉐이커 수조에서 11분 동안 배양한다(쉐이킹 속도 190rpm).11. Seal the lid of the conical tube containing each enzyme and pancreas and incubate for 11 minutes in a 37 ° C shaker bath (shaking speed 190 rpm).
12. 그 후 30초 동안 손으로 강하게 흔든다.12. Then shake your hands strongly for 30 seconds.
13. 효소 활성을 멈추기 위하여 차가운 HBSS로 45ml까지 부피를 조정한다.13. Adjust volume to 45 ml with cold HBSS to stop enzymatic activity.
14. 원심분리한다(1500 rpm, 1분).14. Centrifuge (1500 rpm, 1 min).
15. 세포 펠렛까지 상청액을 버리고, 20ml HBSS로 부드럽게 재부유한다.15. Discard the supernatant up to the cell pellet and gently resuspend with 20 ml HBSS.
16. 그 다음 부유액을 500μm 메쉬 체에 통과시키고, 각각의 튜브의 벽을 헹군 후 다시 30ml HBSS를 메쉬 체에 통과시킨다.16. The suspension is then passed through a 500 μm mesh sieve, rinsing the walls of each tube and again passing 30 ml HBSS through the mesh sieve.
17. 원심분리한다(1500 rpm, 1분).17. Centrifuge (1500 rpm, 1 min).
18. 세포 펠렛까지 상청액을 버리고, 20ml HBSS로 부드럽게 재부유하고, 최종적으로 45ml까지 조정한다.18. Discard the supernatant up to the cell pellet, gently resuspend with 20 ml HBSS and finally adjust to 45 ml.
19. 튜브를 위아래로 3번 정도 뒤집어 주고 원심분리한다(1500 rpm, 1분).19. Turn the tube upside down 3 times and centrifuge (1500 rpm, 1 min).
20. 세포 펠렛까지 상청액을 버린다.20. Discard the supernatant up to the cell pellet.
21. 세포 펠렛 안에 보충된 F-10 배지(35μl 엑세나타이드-4를 35ml 배지에 혼합, 농도 20μM)를 첨가하고 적절히 재부유한다.21. Add F-10 medium (35 μl exenatide-4 mixed in 35 ml medium, concentration 20 μM) supplemented in cell pellet and resuspend appropriately.
22. 하나의 코니칼 튜브로부터 분리된 NPCCs를 네 개의 150mm 페트리-접시에 나누어 담는다(배지 부피 35ml).22. NPCCs isolated from one conical tube are divided into four 150 mm Petri dishes (medium volume 35 ml).
23. 다음 배양을 계속하기 위하여 37℃ 세포배양기에서 배양시킨다.23. Incubate in a 37 ° C. cell culture in order to continue the next culture.
5-4: NPCCs 배양(1일-7일)5-4: NPCCs culture (1-7 days)
5-4-1: 과정5-4-1: Process
1. F-10 배지 및 HBSS를 37℃ 항온수조에 담가둔다.1. Soak F-10 medium and HBSS in 37 ℃ constant temperature water bath.
2. 무균 실험대를 세팅하고 NPCCs를 세척하기 위해 HBSS를 소분한다.2. Set up a sterile bench and subtract HBSS to wash NPCCs.
3. 세포배양기에서 NPCCs 배양 접시를 가져와 현미경으로 세포 형태를 확인한다.3. Take NPCCs culture dish from cell incubator and check cell morphology under microscope.
4. 배지에 포함된 모든 NPCCs를 페트리-접시에서 튜브로 수득한다(첫 번째는 수득하고 코니칼 튜브로 옮기고, 두 번째는 페트리-접시를 HBSS로 두 번 헹군다(7ml/각 회차); 이는 네 개의 페트리-접시로부터 네 개의 코니칼 튜브로 NPCCs를 수득함을 의미한다.4. Obtain all NPCCs contained in the medium into tubes in a petri-dish (first obtained and transferred to conical tubes, secondly rinsed petri-dish twice with HBSS (7ml / each); NPCCs are obtained from four Petri-plates with four conical tubes.
5. 원심분리한다(1500 rpm, 1분, 제동 단계 4).5. Centrifuge (1500 rpm, 1 min, braking step 4).
6. 약 5ml 부피가 될 때까지 상청액을 버린다.6. Discard the supernatant until it is about 5 ml in volume.
7. 각각의 튜브를 재부유하고 하나의 튜브에 모은다(모든 NPCCs 펠렛을 하나의 튜브에 모은다).7. Resuspend each tube and collect in one tube (collect all NPCC pellets in one tube).
8. HBSS로 45ml 부피로 조정하고, 원심분리한다(1500 rpm, 1분, 제동 단계 4).8. Adjust to 45 ml volume with HBSS and centrifuge (1500 rpm, 1 min, braking step 4).
9. 펠렛 부피까지 상청액을 버리고 보충된 배지(엑세나타이드-4)로 적절히 재부유한 다음, 네 개의 150mm 페트리-접시로 나누어 담는다(배지 부피 35ml/접시).9. Discard the supernatant to pellet volume and properly resuspend with supplemented medium (Exenatide-4), then divide into four 150 mm Petri-plates (medium volume 35 ml / dish).
10. 다음 배양을 계속하기 위하여 37℃ 세포배양기에서 배양시킨다.10. Incubate in a 37 ° C. cell culture in order to continue the next culture.
※ 위와 동일한 NPCCs 배양 과정을 따른다: 3일 → 5일 → 7일(총 세포 수 계산).※ Follow the same NPCCs culture as above: 3 days → 5 days → 7 days (total cell count).
5-5: NPCCs 수 계산(7일차)5-5: Count NPCCs (day 7)
5-5-1: 세포 준비5-5-1: Cell Preparation
1. F-10 배지 및 HBSS를 37℃ 항온수조에 담가둔다.1. Soak F-10 medium and HBSS in 37 ℃ constant temperature water bath.
2. 무균 실험대를 세팅하고 NPCCs를 세척하기 위해 HBSS를 소분한다.2. Set up a sterile bench and subtract HBSS to wash NPCCs.
3. 세포배양기에서 NPCCs 배양 접시를 가져와 현미경으로 세포 형태를 확인한다.3. Take NPCCs culture dish from cell incubator and check cell morphology under microscope.
4. 배지에 포함된 모든 NPCCs를 페트리-접시에서 튜브로 수득한다(첫 번째는 수득하고 코니칼 튜브로 옮기고, 두 번째는 페트리-접시를 HBSS로 두 번 헹군다(7ml/각 회차); 이는 네 개의 페트리-접시로부터 네 개의 코니칼 튜브로 NPCCs를 수득함을 의미한다.4. Obtain all NPCCs contained in the medium into tubes in a petri-dish (first obtained and transferred to conical tubes, secondly rinsed petri-dish twice with HBSS (7ml / each); NPCCs are obtained from four Petri-plates with four conical tubes.
5. 원심분리한다(1500 rpm, 1분, 제동 단계 4).5. Centrifuge (1500 rpm, 1 min, braking step 4).
6. 약 5ml 부피가 될 때까지 상청액을 버린다.6. Discard the supernatant until it is about 5 ml in volume.
7. 각각의 튜브를 재부유하고 하나의 튜브에 모은다(모든 NPCCs 펠렛을 하나의 튜브에 모은다).7. Resuspend each tube and collect in one tube (collect all NPCC pellets in one tube).
8. HBSS로 45ml 부피로 조정하고, 원심분리한다(1500 rpm, 1분, 제동 단계 4).8. Adjust to 45 ml volume with HBSS and centrifuge (1500 rpm, 1 min, braking step 4).
9. 5ml 부피까지 상청액을 버리고, 부드럽게 재부유하고, 세포 수 계산을 위해 40ml 부피로 조정한다.9. Discard supernatant up to 5 ml volume, gently resuspend and adjust to 40 ml volume for cell counting.
5-5-2: 과정5-5-2: Course
1. 4ml HBSS를 새로운 50ml 코니칼 튜브에 담는다.1. Pour 4 ml HBSS into a new 50 ml conical tube.
2. 최종 부유액으로부터 1ml 세포 부유액을 얻어서 4ml HBSS에 첨가한다(최종 희석 부피 5ml).2. Obtain 1 ml cell suspension from the final suspension and add to 4 ml HBSS (5 ml final dilution volume).
3. 왼손으로 부드럽게 흔들고 100μl 세포 부유액을 수득하고 세포 수 계산을 위해 60mm 페트리-접시에 선을 긋는다.3. Gently shake with your left hand to obtain 100 μl cell suspension and line 60 mm Petri-dish for cell counting.
4. NPCCs 수 계산 차트(도 4)에 따라 수(IEQ)를 계산한다.4. Calculate the number (IEQ) according to the NPCCs number calculation chart (Figure 4).
이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적 기술은 단지 바람직한 실시태양일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다.The specific parts of the present invention have been described in detail above, and it is apparent to those skilled in the art that such specific descriptions are merely preferred embodiments, and thus the scope of the present invention is not limited thereto. something to do. Thus, the substantial scope of the present invention will be defined by the appended claims and their equivalents.
본 발명에 따른 췌도의 분리 방법을 이용하면 신생돼지로부터 높은 효율로 양질의 췌도를 분리해낼 수 있는바, 이종간 이식을 위한 췌도 분리 기술로서 활용할 수 있을 뿐만 아니라, 신생돼지 췌도의 분리와 배양 및 정도 분석 기술을 개발함으로써, 당뇨병 치료 등 생명의학 분야에서 널리 활용될 수 있다.Using the method for isolating islets according to the present invention can separate high-quality pancreatic islets from newborn pigs with high efficiency, and can be used as a pancreatic islet separation technique for cross-transplantation, as well as isolation and culture and degree of newborn pig islets. By developing analytical techniques, they can be widely used in biomedical fields such as diabetes treatment.
Claims (8)
- 하기 단계를 포함하는 신생돼지의 췌도 분리 방법:How to isolate islets of newborn pigs comprising the following steps:(a) 신생돼지로부터 췌도를 적출하는 단계;(a) extracting the islets from the newborn pigs;(b) 적출한 췌장에 효소를 주입하는 단계; 및(b) injecting enzyme into the isolated pancreas; And(c) 효소의 활성화를 유도하는 단계.(c) inducing activation of the enzyme.
- 제1항에 있어서, 상기 효소는 콜라게나아제 V인 것을 특징으로 하는, 신생돼지의 췌도 분리 방법.The method of claim 1, wherein the enzyme is collagenase V, islet separation method of neonatal pigs.
- 제1항에 있어서, 상기 (c) 단계는 37℃ 수조에서 흔들어 효소의 활성화를 유도하는 것을 특징으로 하는, 신생돼지의 췌도 분리 방법.According to claim 1, wherein the step (c) is shaken in a 37 ℃ water tank, characterized in that to induce the activation of the enzyme, islet separation method of newborn pigs.
- 제1항에 있어서, 상기 (c) 단계 후에 췌도를 배양하는 단계를 더 포함하는 것을 특징으로 하는, 신생돼지의 췌도 분리 방법.The method of claim 1, further comprising culturing the islets after the step (c).
- 제4항에 있어서, 37℃에서 5% 이산화탄소 존재 조건하에서 배양하는 것을 특징으로 하는, 신생돼지의 췌도 분리 방법.The method for separating islets of neonatal pigs according to claim 4, wherein the piglets are cultured at 37 ° C under 5% carbon dioxide.
- 제4항에 있어서, F10 배지에서 배양하는 것을 특징으로 하는, 신생돼지의 췌도 분리 방법.The method for separating islets of neonatal pigs according to claim 4, which is cultured in F10 medium.
- 제1항에 있어서, 행크 평형 염류 용액(HBSS)를 완충액으로 사용하는 것을 특징으로 하는, 신생돼지의 췌도 분리 방법.The method of claim 1, wherein Hank's balanced salt solution (HBSS) is used as a buffer.
- 제1항에 있어서, 신생돼지는 생후 3일 내지 5일 된 것을 특징으로 하는, 신생돼지의 췌도 분리 방법.The method of claim 1, wherein the newborn pigs are 3 to 5 days old.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2016-0166487 | 2016-12-08 | ||
KR1020160166487A KR101914837B1 (en) | 2016-12-08 | 2016-12-08 | Method for Isolating Pancreatic Islet of Neonatal Piglets |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018105805A1 true WO2018105805A1 (en) | 2018-06-14 |
Family
ID=62491227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2017/000273 WO2018105805A1 (en) | 2016-12-08 | 2017-01-09 | Method for isolating islet of newborn pig |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101914837B1 (en) |
WO (1) | WO2018105805A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114081694A (en) * | 2021-12-15 | 2022-02-25 | 赛诺医疗科学技术股份有限公司 | Vascular degrading solution, obtaining method and application of intravascular stent after animal test |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997039107A2 (en) * | 1996-04-12 | 1997-10-23 | The Governors Of The University Of Alberta | Methods for increasing the maturation of cells |
KR100686383B1 (en) * | 2005-08-17 | 2007-02-22 | 피더블유제네틱스코리아 주식회사 | Isolation Method of Pig Islet Cells for Xenograft |
KR20070095956A (en) * | 2004-12-22 | 2007-10-01 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | How to separate pancreatic islets |
KR20130091260A (en) * | 2010-07-13 | 2013-08-16 | 가부시키가이샤 오츠카 세이야쿠 고죠 | Pancreatic islet separation method, and protective solution for protecting pancreatic islet tissue |
-
2016
- 2016-12-08 KR KR1020160166487A patent/KR101914837B1/en active Active
-
2017
- 2017-01-09 WO PCT/KR2017/000273 patent/WO2018105805A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997039107A2 (en) * | 1996-04-12 | 1997-10-23 | The Governors Of The University Of Alberta | Methods for increasing the maturation of cells |
KR20070095956A (en) * | 2004-12-22 | 2007-10-01 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | How to separate pancreatic islets |
KR100686383B1 (en) * | 2005-08-17 | 2007-02-22 | 피더블유제네틱스코리아 주식회사 | Isolation Method of Pig Islet Cells for Xenograft |
KR20130091260A (en) * | 2010-07-13 | 2013-08-16 | 가부시키가이샤 오츠카 세이야쿠 고죠 | Pancreatic islet separation method, and protective solution for protecting pancreatic islet tissue |
Non-Patent Citations (1)
Title |
---|
PARK, SOL JI ET AL.: "Functional Improvement of Porcine Neonatal Pancreatic Cell Clusters via Conformal Encapsulation Using an Air-driven Encapsulator", EXPERIMENTAL AND MOLECULAR MEDICINE, vol. 44, no. 1, January 2012 (2012-01-01), pages 20 - 25, XP055510111 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114081694A (en) * | 2021-12-15 | 2022-02-25 | 赛诺医疗科学技术股份有限公司 | Vascular degrading solution, obtaining method and application of intravascular stent after animal test |
Also Published As
Publication number | Publication date |
---|---|
KR101914837B1 (en) | 2018-11-02 |
KR20180065512A (en) | 2018-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Xu et al. | Encapsulated three-dimensional culture supports development of nonhuman primate secondary follicles | |
JP2813467B2 (en) | Cell culture methods and media | |
Nagata et al. | Evaluation of insulin secretion of isolated rat islets cultured in extracellular matrix | |
Gouk et al. | Cryopreservation of mouse testicular tissue: prospect for harvesting spermatogonial stem cells for fertility preservation | |
CN106520676B (en) | The method and its application of human amnion membrane are prepared from Human plactnta amnion | |
WO1991009936A1 (en) | Proliferated neuron progenitor cell product and process | |
JPH09509827A (en) | Regeneration and utilization of functional human tissue | |
WO2020111507A1 (en) | Composition for transplantation of organoid | |
WO2013085303A1 (en) | Canine amniotic membrane-derived multipotent stem cells | |
WO2018105805A1 (en) | Method for isolating islet of newborn pig | |
Abraham et al. | In vitro culture of Dirofilaria immitis third-and fourth-stage larvae under defined conditions | |
Velasco et al. | Rat pancreatic beta-cell culture | |
ES2299417T3 (en) | METHOD FOR PRODUCING PREPARATIONS OF MATURE AND IMMATURE PANCREATIC ENDOCRINE CELLS, PREPARATION OF CELLS AND ITS USE FOR THE TREATMENT OF MELLITUS DIABETES. | |
Mansour et al. | The impact of spermatozoa preincubation time and spontaneous acrosome reaction in intracytoplasmic sperm injection: a controlled randomized study | |
WO2013077639A1 (en) | Equine amniotic membrane-derived mesenchymal stem cells | |
BRPI0708039A2 (en) | feeder cells derived from tissue stem cells | |
WO2019216450A1 (en) | Method for culturing stem cells secreting anti-inflammatory components, and anti-inflammatory composition containing said stem cell culture medium | |
WO2018092962A1 (en) | Oxygen-generating scaffold and method for producing same | |
WO2017078439A1 (en) | Pharmaceutical composition for treating diabetes, comprising pancreatic islet cells and elastin-like artificial extracellular matrix | |
US8372644B2 (en) | Method for growing adult cells | |
WO2020130615A1 (en) | Medium composition for inducing differentiation of hepatic stem cells into cholangiocytes and use thereof | |
WO2014119893A1 (en) | Method for inducing tailored pluripotent stem cells using extract of plant stem cells or plant dedifferentiated stem cells, and pluripotent stem cells produced by means of the method | |
Shenvi et al. | A rat primary hepatocyte culture model for aging studies | |
CN106609258A (en) | Rat nasal mucosa epithelial cell isolation and culture method | |
Galas | Primary culture of ovarian cells for research on cell interactions in the hormonal control of steroidogenesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17879618 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17879618 Country of ref document: EP Kind code of ref document: A1 |